2.1
Selinexor (Nexpovio, Menarini Stemline) is indicated 'in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy'.
2 Information about selinexor
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for selinexor.
Price
2.3
The list price for selinexor is £9,200 per 20‑tablet pack of 20 mg tablets (excluding VAT; BNF online accessed March 2024). Other pack sizes are available.
2.4
The company has a commercial arrangement. This makes selinexor available to the NHS with a discount. The size of the discount is commercial in confidence.